Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients

Inclusion criteria: 1. Relapsed or refractory CD19-positive non-Hodgkin lymphoma (NHL) patients. 1 Diffuse large B lymphoma (DLBCL), follicular lymphoma (FL), primary mediastinal B-cell lymphoma (PMBCL) patients meet one of the following conditions: I Patients who have relapsed or are refractory after at least 2 previous treatments; II Patients who have relapsed after transplantation. 2 Patients with relapsed or refractory mantle cell lymphoma after at least one treatment. 2. Patients must have evaluable disease evidence; 3. Age ≥ 18 years old; 4. The expected life span is more than 3 months; 5. ECOG score 0-2 points (see Attachment 2); 6. Women of childbearing age have a negative blood pregnancy test before the start of the trial and agree to have effective contraceptive measures during the trial until the last follow-up; 7. Those who voluntarily participate in the trial and sign the informed consent. Exclusion criteria: 1. Patients with high-risk organ involvement: tumors invade one of the central nervous system, gastrointestinal tract, lungs, pericardium, and large vessels; 2. Those who have a graft-versus-host response and need to use immunosuppressive drugs; or who have a disease of the autoimmune system; 3. Use chemotherapy or radiotherapy within 3 days before the blood collection period; 4. Those who have used systemic steroids within the 5 days prior to the blood sampling period (except recently or currently using inhaled steroids); 5. Use stimulating bone marrow hematopoietic cells to produce drugs (whitening needles, etc.) within 5 days before the blood collection period; 6. Those who have previously used any gene therapy products; 7. History of epilepsy or other diseases of the central nervous system; 8. New York Heart Association (NYHA) class III or above (see Annex 3); 9. creatinine\> 1.5 times the upper limit of normal or ALT / AST\> 3 times the upper limit of normal or bilirubin\> 2 times the normal upper limit; 10. active Hepatitis B or Hepatitis C virus, HIV or other untreated active infections; 11. pregnant or lactating women; 12. suffer from other uncontrolled diseases that the researcher considers inappropriate; 13. Any condition that the investigator believes may increase the subject's risk or interfere with the test results.